Safety Considerations in Cannabinoid-Based Medicine.
cannabidiol
cannabinoid
cannabis
safety
Δ9-tetrahydrocannabinol
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
08
2020
accepted:
05
10
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
11
12
2020
Statut:
epublish
Résumé
Cannabinoids are a diverse class of chemical compounds that are increasingly recognized as potential therapeutic options for a range of conditions. While many studies and reviews of cannabinoids focus on efficacy, safety is much less well reported. Overall assessment of the safety of cannabinoid-based medicines is confounded by confusion with recreational cannabis use as well as different study designs, indications, dosing, and administration methods. However, clinical studies in registered products are increasingly available, and this article aims to discuss and clarify what is known regarding the safety profiles of cannabinoid-based medicines, focusing on the medical and clinical safety evidence and identifying areas for future research. The two most well-studied cannabinoids are Δ
Identifiants
pubmed: 33299341
doi: 10.2147/IJGM.S275049
pii: 275049
pmc: PMC7720894
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1317-1333Informations de copyright
© 2020 Gottschling et al.
Déclaration de conflit d'intérêts
Sven Gottschling has received consultancy fees from Bioevents, Bionorica, Biotest, Boehringer Ingelheim, Cogitando, Experten-Futrue, Grünenthal, Hexal, IQQ Institut, Kyowa Kirin, MedConcept, Novartis, Roche, Sandoz, Spectrum Therapeutics, and Tilray. Oyedeji Ayonrinde has no disclosures to declare. Arun Bhaskar has received consultancy fees from Spectrum Therapeutics. Marc Blockman has received consultancy fees from Spectrum Therapeutics. Oscar D’Agnone has received consultancy fees from Spectrum Therapeutics. Danial Schecter is a former employee of Spectrum Therapeutics, a former employee of Canopy Growth Corp from February 2019 to March 2020 and has provided consulting services both prior and after this, was previously Chief Medical Advisor of AusCann, and received honoraria from and provided consulting services for the following: Aleafia Health Inc, Shoppers Drug Mart, Khiron, Tilray, and Organigram, outside the submitted work. Luis David Suárez Rodríguez has received consultancy fees from Spectrum Therapeutics and funding from the Asociacion Mexicana de Medicina Cannabinoide AC, and reports personal fees and non-financial support from Asociación Mexicana de Medicina Cannabinoide AC, outside the submitted work; and is the current President of the Asociación Mexicana de Medicina Cannabinoide AC. Sherry Yafai has received consultancy fees from Canopy Growth. Claude Cyr has received consultancy fees from Aurora, Shoppers/Inventiv, Spectrum Therapeutics, and Tilray. The authors report no other potential conflicts of interest for this work.
Références
Clin Transl Sci. 2019 May;12(3):236-239
pubmed: 30791226
Am J Epidemiol. 2015 Sep 15;182(6):473-81
pubmed: 26283092
Drug Alcohol Depend. 2019 Jan 1;194:136-142
pubmed: 30439610
BMC Cancer. 2015 Nov 11;15:897
pubmed: 26560314
Int J Cancer. 2015 Feb 15;136(4):894-903
pubmed: 24947688
Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187
pubmed: 25676540
Pharmacol Ther. 2013 Apr;138(1):18-37
pubmed: 23261685
J Pain. 2015 Dec;16(12):1233-1242
pubmed: 26385201
Eur J Neurol. 2011 Sep;18(9):1122-31
pubmed: 21362108
Nat Prod Rep. 2016 Nov 23;33(12):1357-1392
pubmed: 27722705
Pediatrics. 2017 Nov;140(5):
pubmed: 29061872
Drug Alcohol Depend. 2017 Aug 1;177:1-13
pubmed: 28549263
Drug Alcohol Depend. 2017 Aug 1;177:136-144
pubmed: 28599212
J Neuroendocrinol. 2008 May;20 Suppl 1:10-4
pubmed: 18426493
PLoS One. 2013 Oct 24;8(10):e76635
pubmed: 24204649
Medicines (Basel). 2018 Dec 23;6(1):
pubmed: 30583596
Pharmacol Ther. 2017 Jul;175:133-150
pubmed: 28232276
Nat Rev Drug Discov. 2004 Sep;3(9):771-84
pubmed: 15340387
Ann Palliat Med. 2018 Oct;7(4):463-477
pubmed: 30180728
Drug Alcohol Depend. 2019 Sep 1;202:191-199
pubmed: 31357120
Oncologist. 2019 Apr;24(4):549-554
pubmed: 30670598
Eur J Intern Med. 2018 Mar;49:12-19
pubmed: 29307505
Neurol Res. 2010 Jun;32(5):451-9
pubmed: 20307378
J Neurol. 2013 Jan;260(1):285-95
pubmed: 22878432
Can Fam Physician. 2020 Feb;66(2):98-103
pubmed: 32060189
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78
pubmed: 23108553
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1466-71
pubmed: 16876926
J Pain. 2008 Feb;9(2):164-73
pubmed: 17974490
Clin Toxicol (Phila). 2016 Nov;54(9):840-846
pubmed: 27418198
J Clin Med. 2019 Jul 08;8(7):
pubmed: 31288397
Horm Behav. 2010 Jun;58(1):91-9
pubmed: 19733173
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):214-218
pubmed: 31559336
Cannabis Cannabinoid Res. 2018 Sep 01;3(1):179-189
pubmed: 30221197
Clin J Pain. 2016 Dec;32(12):1036-1043
pubmed: 26889611
J Med Toxicol. 2014 Sep;10(3):269-79
pubmed: 24648180
Ther Clin Risk Manag. 2016 Nov 11;12:1667-1675
pubmed: 27956834
Eur Neurol. 2017;78(5-6):320-329
pubmed: 29073592
J Am Acad Child Adolesc Psychiatry. 2017 Feb;56(2):124-132.e2
pubmed: 28117058
PLoS One. 2017 Nov 16;12(11):e0187795
pubmed: 29145417
CMAJ. 2008 Jun 17;178(13):1669-78
pubmed: 18559804
Epilepsia. 2018 Aug;59(8):1540-1548
pubmed: 29998598
Eur J Neurol. 2007 Mar;14(3):290-6
pubmed: 17355549
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
CNS Drugs. 2018 Nov;32(11):1053-1067
pubmed: 30374683
Curr Drug Metab. 2016;17(3):206-26
pubmed: 26651971
Lancet. 2018 Mar 17;391(10125):1085-1096
pubmed: 29395273
Pain. 2003 Nov;106(1-2):169-72
pubmed: 14581124
J Clin Pharmacol. 1981 Aug-Sep;21(S1):377S-382S
pubmed: 6117575
Sci Rep. 2015 Jan 30;5:8126
pubmed: 25634572
Epilepsia. 2019 Feb;60(2):294-302
pubmed: 30582156
J Pharmacol Exp Ther. 1990 Jun;253(3):1002-9
pubmed: 2162942
Lancet Neurol. 2016 Mar;15(3):270-8
pubmed: 26724101
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):139-157
pubmed: 31579832
Curr Med Res Opin. 2007 Mar;23(3):533-43
pubmed: 17355735
J Psychopharmacol. 2013 Jan;27(1):19-27
pubmed: 23042808
Int J Drug Policy. 2015 Feb;26(2):135-42
pubmed: 25168081
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
JAMA Psychiatry. 2018 Jun 1;75(6):585-595
pubmed: 29710074
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Addiction. 2010 Mar;105(3):494-503
pubmed: 20402993
J Headache Pain. 2018 May 24;19(1):37
pubmed: 29797104
Chem Biodivers. 2007 Aug;4(8):1770-804
pubmed: 17712819
JAMA. 2019 Jul 9;322(2):167-169
pubmed: 31211824
Drug Alcohol Depend. 2020 Mar 1;208:107771
pubmed: 31952821
Obstet Gynecol. 2016 Oct;128(4):713-23
pubmed: 27607879
Pain. 2019 Jan;160(1):136-150
pubmed: 30157131
N Engl J Med. 2017 May 25;376(21):2011-2020
pubmed: 28538134
Neurology. 2014 Mar 25;82(12):1083-92
pubmed: 24663230
J Headache Pain. 2012 Nov;13(8):677-84
pubmed: 23070400
Mult Scler. 2006 Oct;12(5):639-45
pubmed: 17086911
BMJ. 2008 Jan 26;336(7637):199-201
pubmed: 18182416
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
J Neurol. 2015 Jan;262(1):27-40
pubmed: 25270679
Int J Infect Dis. 2017 Jun;59:124-130
pubmed: 28315398
Anesth Analg. 2010 Feb 1;110(2):604-10
pubmed: 20007734
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
Addict Behav. 1982;7(4):363-71
pubmed: 7183189
Clin Pharmacol Ther. 2011 Dec;90(6):844-51
pubmed: 22048225
Cannabis Cannabinoid Res. 2017 Jun 01;2(1):160-166
pubmed: 28861516
Epilepsia. 2019 Mar;60(3):419-428
pubmed: 30740695
J Neuroimmune Pharmacol. 2015 Jun;10(2):293-301
pubmed: 25796592
Pain Res Manag. 2005 Autumn;10 Suppl A:31A-7A
pubmed: 16237480
Neurotoxicol Teratol. 1990 Mar-Apr;12(2):161-8
pubmed: 2333069
J Pain Symptom Manage. 1997 Jul;14(1):7-14
pubmed: 9223837
Handb Exp Pharmacol. 2005;(168):299-325
pubmed: 16596779
Am J Public Health. 2017 Apr;107(4):601-606
pubmed: 28207342
Eur J Intern Med. 2018 Mar;49:44-50
pubmed: 29398248
Complement Ther Clin Pract. 2006 Feb;12(1):27-33
pubmed: 16401527
Eur J Pain. 2018 Oct;22(9):1547-1564
pubmed: 30074291
Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900
pubmed: 31222854
Circulation. 2001 Jun 12;103(23):2805-9
pubmed: 11401936
CMAJ. 2020 Mar 2;192(9):E206
pubmed: 32122975
Eur J Pharmacol. 1974 Sep;28(1):172-7
pubmed: 4609777
Mult Scler. 2004 Aug;10(4):434-41
pubmed: 15327042
Pain Res Manag. 2014 Nov-Dec;19(6):328-35
pubmed: 25479151
Pain Res Treat. 2017;2017:9081802
pubmed: 29410915
JAMA Intern Med. 2018 May 1;178(5):673-679
pubmed: 29610827
Aust Fam Physician. 2013 Jul;42(7):481-5
pubmed: 23826601
Pain Med. 2019 Nov 1;20(11):2083-2085
pubmed: 31529092
Br J Pharmacol. 2008 Jan;153(2):286-9
pubmed: 17952109
Ann Emerg Med. 2003 Sep;42(3):365-9
pubmed: 12944889
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35
pubmed: 30661105
Can Fam Physician. 2018 Feb;64(2):111-120
pubmed: 29449241
Drug Alcohol Depend. 2010 Jul 1;110(1-2):137-43
pubmed: 20347232
JAMA Intern Med. 2019 Jul 15;:
pubmed: 31305874
Mult Scler. 2012 Feb;18(2):219-28
pubmed: 21878454
Addiction. 2016 Aug;111(8):1348-59
pubmed: 26878835
Cochrane Database Syst Rev. 2018 Mar 07;3:CD012182
pubmed: 29513392